

## Oncology Today with Dr Neil Love: Key Presentations on Non-Hodgkin and Hodgkin Lymphomas from the 2020 ASH Annual Meeting — Issue 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following drug types best describes the mechanism of action of mosunetuzumab?
  - a. EZH2 inhibitor
  - b. Bispecific antibody targeting CD20/CD3
  - c. CAR (chimeric antigen receptor) T-cell therapy
2. Is the novel Bruton tyrosine kinase inhibitor LOXO-305 a covalent or noncovalent inhibitor?
  - a. Noncovalent inhibitor
  - b. Covalent inhibitor
3. Which of the following agents is a CD19-directed monoclonal antibody that recently received FDA approval in combination with lenalidomide for transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma?
  - a. Venetoclax
  - b. Selinexor
  - c. Tafasitamab
  - d. Tazemetostat
4. The 5-year update of the Phase III ECHELON-2 trial demonstrated sustained progression-free and overall survival benefits with which of the following regimens in comparison to CHOP for patients with previously untreated CD30-expressing peripheral T-cell lymphoma?
  - a. R-CHOP
  - b. Brentuximab vedotin (BV) with CHP (cyclophosphamide/doxorubicin/prednisone)
  - c. BV with doxorubicin/bleomycin/vinblastine/dacarbazine
  - d. BV with doxorubicin/vinblastine/dacarbazine